Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim is to assess the efficacy and specific safety in an observational study of patients with Chronic hepatitis D (CHD) with prospective follow-up, with antiviral treatment of 2 mg Bulevirtide (BLV) +/- PEG-IFNα-2a and +/- NA given as part of the patient's routine medical care. Also, explorative endpoints of biomarkers in peripheral blood, saliva, fecal sample and/or intrahepatic markers/signatures, and quality of life outcomes will be assessed.
Chronic hepatitis D (CHD) is considered to be the most severe form of hepatitis. It is a rare disease in European Union countries, with status of an orphan disease. Historically, only pegylated interferon alfa-2a (PEG-IFNα-2a) +/- nucleos(t)ide analogues (NA) have been used off-label for treatment of CHD, with insufficient virological response and frequent relapse. The first in class entry inhibitor for treatment of CHD, bulevirtide (BLV), product name Hepcludex) has received status of conditional marketing authorization by the European Medical Agency (EMA) in July 2020.
This conditional approval was based on two phase 2 studies, with limited sample sizes. A phase 3 clinical trial of 150 participants is ongoing.
Besides need of more efficacy and safety data, knowledge about immunological cellular response in BLV treated and identification of biomarkers for treatment response is needed. Observational studies with biological samplings are thus needed.
We aimed therefore to assess the efficacy and specific safety in an observational study with prospective follow-up, with antiviral treatment of 2 mg BLV +/- PEG-IFNα-2a and +/- NA given as part of the patient's routine medical care. Also, explorative endpoints of biomarkers in peripheral blood, saliva, fecal sample and/or intrahepatic markers/signatures, and quality of life outcomes will be assessed.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bulevirtide | Drug | Hepcludex, 2 mg daily subcutaneous injection |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients with virological response of Hepatitis D virus (HDV) RNA < Limit of Detection (LoD) at FU 12 months after End of Treatment (EOT). | Measurement of virological response of HDV RNA < LoD | Continuously, up to 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients with virological response of HDV RNA < LoD | Percentage of patients with virological response of HDV RNA < LoD at at month 1, 3 and every 3 months after treatment start, and FU month 3, 6, and 9 after EOT. | At Baseline, 1 and 3 months, every 3 months after treatment start up to 9 months after date of EOT. |
Not provided
Inclusion Criteria:
Age > 18 years
Diagnosis of chronic HBV/HDV co-infection.
Have compensated liver disease (presence of portal hypertension without ongoing hepatic decompensation as ascites, variceal bleeding and hepatic encephalopathy allowed).
Have indication for treatment of BLV, or already treated with BLV.
For female* participants:
Male participants must agree to use a highly effective contraception (double barrier method or barrier contraception in combination with hormonal or intrauterine contraceptive used by female partners) throughout the treatment period and for 6 months after last dose of the drugs in the study.
Participants who are willing to give written informed consent
Exclusion Criteria:
Not provided
Not provided
Not provided
Males and females from the age of 18 diagnosed with chronic hepatitis D
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Soo Aleman, MD, PhD | Contact | +46 72-595 72 25 | soo.aleman@regionstockholm.se |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Karolinska University Hospital, Department of Infectious Diseases | Recruiting | Stockholm | Sweden |
Not provided
| ID | Term |
|---|---|
| D019701 | Hepatitis D, Chronic |
| ID | Term |
|---|---|
| D003699 | Hepatitis D |
| D006525 | Hepatitis, Viral, Human |
| D014777 | Virus Diseases |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C000718249 | bulevirtide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Biological sampling of blood, saliva and fecal samples and liver tissue (liver biopsy or fine needle aspiration
| Percentage of patients with Hepatitis B surface antigen (HBsAg) < LoD |
Percentage of patients with HBsAg < LoD at month 1 and 3, and every 3 months after treatment start, and FU month 3, 6, 9 and 12 after EOT. |
| At Baseline, 1 and 3 months, every 3 months after treatment start up to 12 months after date of EOT. |
| Change of HBsAg from baseline | Change of HBsAg from baseline every 3 months during study period. | From Baseline every 3 months until end of study. |
| Percentage of patients with HDV RNA < LoD or HDV RNA reduction of at least 2 log10 compared to baseline | Percentage of patients with HDV RNA < LoD or HDV RNA reduction of at least 2 log10 compared to baseline, at month 1 and 3, and every 3 months after treatment start, and FU month 3, 6, 9 and 12 after EOT. | At Baseline, 1 and 3 months, every 3 months after treatment start up to 12 months after date of EOT. |
| Percentage of patients with virological relapse, defined as HDV RNA < LoD at EOT and increase of HDV RNA to > LoD after EOT | Percentage of patients with virological relapse, defined as HDV RNA < LoD at EOT and increase of HDV RNA to > LoD after EOT, after EOT, at FU month 3, 6, 9 and 12 after EOT. | At 0, 3, 6, 9 and 12 months after date of EOT. |
| Percentage of patients with appearance of hepatitis B surface antibody (anti-HBs) | Percentage of patients with appearance of hepatitis B surface antibody (anti-HBs) at EOT, and FU month 3, 6, 9 and 12 after EOT. | At 0, 3, 6, 9 and 12 months after date of EOT. |
| Percentage of patients with HBV DNA level < LoD | Percentage of patients with HBV DNA level < LoD every 3 months during study period. | From Baseline every 3 months until end of study. |
| Percentage of patients with biochemical response, defined as normalization of alanine transaminase (ALT) | Percentage of patients with biochemical response, defined as normalization of alanine transaminase (ALT), at month 1, 3 and every 3 months during treatment, and FU month 3, 6, 9 and 12 after EOT. | At Baseline, 1 and 3 months, every 3 months up to 12 months after date of EOT. |
| Percentage of patients with combined response, defined as HDV RNA < LoD or HDV RNA reduction of at least 2 log10 compared to baseline and Alanine Aminotransferase (ALT) normalization | Percentage of patients with combined response, defined as HDV RNA < LoD or HDV RNA reduction of at least 2 log10 compared to baseline and ALT normalization, at month 1, 2 and 3, and every 3 months after treatment start, and FU month 3, 6, 9 and 12 after EOT. | At Baseline, at 1, 2 and 3 months, every 3 months up to 12 months after date of EOT. |
| Change of liver elasticity measurement level and percentage of AE of special interest | Change of liver elasticity measurement level from baseline compared to the level at every 6 months during on-treatment, EOT, and FU month 6 and 12 after EOT. Percentage of AE of special interest: 1. Liver-related event, defined as new diagnoses of liver cirrhosis, HCC, or hepatic decompensation (ascites, variceal bleeding or hepatic encephalopathy); 2. Event of ≥ grade 3 hematological AE (in IFN treated); 3. Event of thyroid disorder (in IFN treated); 4. Event of injection site reaction; 5. Event of≥ grade 3 ALT increase. | At Baseline, every 6 months until 12 months after date of EOT. |
| Percentage of missed BLV doses during treatment | Percentage of missed BLV doses during treatment. | Continuously during treatment period until date of EOT. |
| Percentage of patients with early discontinuation of treatment | Percentage of patients with early discontinuation of treatment and the reasons. | Continuously during treatment period until date of EOT. |
| Serious Adverse Events | Percentage of patients with SAE. | Continuously during study period until end of study. |
| D012327 |
| RNA Virus Infections |
| D006521 | Hepatitis, Chronic |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |